Tuesday, December 17, 2019 8:42:08 PM
All posts are opinions. I only take long positions on securities. Not a professional by any stretch.
Recent MIRM News
- Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference • Business Wire • 05/07/2024 08:10:00 PM
- Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC • Business Wire • 05/07/2024 12:30:00 PM
- Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 • Business Wire • 05/01/2024 08:10:00 PM
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/11/2024 01:30:00 AM
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome • Business Wire • 04/02/2024 12:30:00 PM
- LIVMARLI (solution orale de maralixibat) de Mirum Pharmaceuticals reçoit une recommandation de remboursement positive de l’ACMTS du Canada pour le traitement du prurit cholestatique chez les patients atteints du syndrome d’Alagille • Business Wire • 04/02/2024 12:30:00 PM
- Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors • GlobeNewswire Inc. • 03/25/2024 11:00:00 AM
- Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis • Business Wire • 03/13/2024 10:00:00 PM
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/09/2024 12:30:00 AM
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences • Business Wire • 03/05/2024 01:00:00 PM
- Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI • Business Wire • 02/29/2024 01:30:00 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 02/28/2024 10:01:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:05:28 PM
- Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update • Business Wire • 02/28/2024 09:03:00 PM
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024 • Business Wire • 02/21/2024 09:05:00 PM
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 02/10/2024 02:15:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 02:12:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 02:10:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:28:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:10:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:10:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:10:19 AM
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/20/2024 02:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:15:59 PM
- Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer • Business Wire • 01/16/2024 01:30:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM